Pyxis Oncology (PYXS) Liabilities and Shareholders Equity (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $91.5 million in Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $91.5 million, down 41.77% year-over-year; the trailing twelve-month figure through Dec 2025 was $456.2 million (down 41.59% YoY), and the FY2025 annual result was $91.5 million, down 41.77% from the prior year.
• Liabilities and Shareholders Equity retreated to $91.5 million in Q4 2025 per PYXS's latest filing, from $105.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $280.0 million in Q4 2021 and troughed at $91.5 million in Q4 2025.
• A 5-year average of $183.7 million and a median of $184.7 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2021 and 2025: Liabilities and Shareholders Equity jumped 2658.56% in 2021, then tumbled 45.93% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $280.0 million in 2021, then declined by 24.51% to $211.4 million in 2022, then slipped by 17.81% to $173.7 million in 2023, then slipped by 9.52% to $157.2 million in 2024, then slumped by 41.77% to $91.5 million in 2025.
• Business Quant data shows PYXS's Liabilities and Shareholders Equity at $91.5 million in Q4 2025, $105.6 million in Q3 2025, and $123.2 million in Q2 2025.